Topical therapies were effective in most cases, but a change of MS treatment or initiation of psoriasis-specific immunotherapies, including the interleukin-17A-antibody secukinumab, was required in four patients.<h4>Conclusion</h4>Psoriasis onset or worsening during BCDT is rare. The gene discussed is IL17A; the disease is myeloid sarcoma.